Molecular Dynamics Simulations Provide Insight into the Loading Efficiency of Proresolving Lipid Mediators Resolvin D1 and D2 in Cell Membrane-Derived Nanovesicles

被引:12
作者
Jeevan, B. G. C. [1 ]
Szlenk, Christopher T. [1 ]
Gao, Jin [1 ]
Dong, Xinyue [1 ]
Wang, Zhenjia [1 ]
Natesan, Senthil [1 ]
机构
[1] Washington State Univ, Dept Pharmaceut Sci, Coll Pharm & Pharmaceut Sci, Spokane, WA 99202 USA
基金
美国国家卫生研究院;
关键词
resolvins; cell membrane-derived nanovesicles; membrane partitioning; molecular dynamics simulation; drug delivery; nanotechnology; GENERAL FORCE-FIELD; ANTIINFLAMMATORY PROPERTIES; FATTY-ACIDS; RESOLUTION; RECEPTOR; INFLAMMATION; DELIVERY; E1; OPPORTUNITIES; AUTOMATION;
D O I
10.1021/acs.molpharmaceut.0c00299
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Resolvins D1 and D2 (RvDs) are structural isomers and metabolites of docosahexaenoic acid, an omega-3 fatty acid, enzymatically produced in our body in response to acute inflammation or microbial invasion. Resolvins have been shown to play an essential role in the resolution of inflammation, tissue repair, and return to homeostasis and thus are actively pursued as potential therapeutics in treating inflammatory disorders and infectious diseases. However, effective in vivo delivery of RvDs continues to be a challenging task. Recent studies demonstrated that RvD1 or RvD2 loaded in cell membrane-derived nanovesides significantly increased therapeutic efficacy in treating murine peritonitis and ischemic stroke, respectively. The mechanistic details of how the subtle structural difference between RvD1 and RvD2 alters their molecular interactions with the membrane lipids of the nanovesides and thus affects the loading efficiency remain unknown. Here, we report the encapsulation profiles of the neutral and ionized species of both RvD1 and RvD2 determined with the cell membrane-derived nanovesides at pH values 5.4 and 7.4, respectively. Also, we performed microsecond time-scale all-atom molecular dynamics (MD) simulations in explicit water to elucidate the molecular interactions of both neutral and ionized species of RvD1 and RvD2 with the lipid bilayer using a model membrane system, containing 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and cholesterol. We found that the differences in the position and chirality of hydroxyl groups in RvD1 and RvD2 affected their location, orientation, and conformations within the bilayer. Surprisingly, the deprotonation of their carboxyl group caused their orientation and conformation to change from a fully extended one that is oriented in parallel to the membrane plane to a J-shaped bent conformation that is oriented perpendicular to the bilayer plane. Our studies offer valuable insight into the molecular interactions of RvD1/D2 with the lipid bilayer in atomistic details and provide a mechanistic explanation for the observed differences in the encapsulation profiles of RvD1 and RvD2, which may facilitate the rational design of nanovesicle-based therapeutics for treating inflammatory diseases.
引用
收藏
页码:2155 / 2164
页数:10
相关论文
共 73 条
  • [1] Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1
    Arita, M
    Bianchini, F
    Aliberti, J
    Sher, A
    Chiang, N
    Hong, S
    Yang, R
    Petasis, NA
    Serhan, CN
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (05) : 713 - 722
  • [2] Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation
    Arita, Makoto
    Ohira, Taisuke
    Sun, Yee-Ping
    Elangovan, Siva
    Chiang, Nan
    Serhan, Charles N.
    [J]. JOURNAL OF IMMUNOLOGY, 2007, 178 (06) : 3912 - 3917
  • [3] Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions
    Arita, Makoto
    Oh, Sungwhan F.
    Chonan, Tomomichi
    Hong, Song
    Elangovan, Siva
    Sun, Yee-Ping
    Uddin, Jasim
    Petasis, Nicos A.
    Serhan, Charles N.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (32) : 22847 - 22854
  • [4] Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation
    Arnardottir, Hildur H.
    Dalli, Jesmond
    Norling, Lucy V.
    Colas, Romain A.
    Perretti, Mauro
    Serhan, Charles N.
    [J]. JOURNAL OF IMMUNOLOGY, 2016, 197 (06) : 2362 - 2368
  • [5] Doxil® - The first FDA-approved nano-drug: Lessons learned
    Barenholz, Yechezkel
    [J]. JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) : 117 - 134
  • [6] Specialized pro-resolving mediators: endogenous regulators of infection and inflammation
    Basil, Maria C.
    Levy, Bruce D.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2016, 16 (01) : 51 - 67
  • [7] In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis
    Benabdoun, Houda Abir
    Kulbay, Merve
    Rondon, Elsa-Patricia
    Vallieres, Francis
    Shi, Qin
    Fernandes, Julio
    Fahmi, Hassan
    Benderdour, Mohamed
    [J]. ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [8] Resolvin D2 elevates cAMP to increase intracellular [Ca2+] and stimulate secretion from conjunctival goblet cells
    Botten, Nora
    Hodges, Robin R.
    Li, Dayu
    Bair, Jeffrey A.
    Shatos, Marie A.
    Utheim, Tor P.
    Serhan, Charles N.
    Dartt, Darlene A.
    [J]. FASEB JOURNAL, 2019, 33 (07) : 8468 - 8478
  • [9] The resolution of inflammation
    Buckley, Christopher D.
    Gilroy, Derek W.
    Serhan, Charles N.
    Stockinger, Brigitta
    Tak, Paul P.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2013, 13 (01) : 59 - 66
  • [10] Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
    Calder, Philip C.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (03) : 645 - 662